Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

66.67USD
4:00pm EDT
Change (% chg)

$0.10 (+0.15%)
Prev Close
$66.57
Open
$66.71
Day's High
$66.85
Day's Low
$65.63
Volume
342,321
Avg. Vol
770,095
52-wk High
$140.07
52-wk Low
$60.22

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $14,110.79
Shares Outstanding(Mil.): 211.97
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 236.60 32.60
EPS (TTM): -0.79 -- --
ROI: -10.36 -7.50 12.74
ROE: -12.89 -10.27 14.66

BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share

* INCYTE REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS

May 01 2018

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

Apr 24 2018

BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration

* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

Apr 24 2018

UPDATE 2-FDA panel against higher dose of Lilly-Incyte arthritis drug

* Approval in only 2 mg dose limits commercial potential- analysts

Apr 23 2018

FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug

April 23 A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.

Apr 23 2018

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

Apr 19 2018

UPDATE 2-Incyte tumbles after combo therapy with Merck fails study

April 6 Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.

Apr 06 2018

Incyte, Merck melanoma combo therapy fails study, shares slide

Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

Apr 06 2018

Incyte's combo therapy for skin cancer fails in late-stage study

April 6 Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Co's Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study.

Apr 06 2018

BRIEF-Incyte, Merck Provide Update On Phase 3 Study

* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Apr 06 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.89 -0.08
Abbott Laboratories (ABT.N) $62.51 +0.67
Amgen, Inc. (AMGN.OQ) $177.96 -1.98
Biogen Inc (BIIB.OQ) $284.41 +0.66
Roche Holding Ltd. (ROG.S) CHF219.00 -0.25
Roche Holding Ltd. (RO.S) CHF223.40 0.00
Sanofi SA (SASY.PA) €65.78 -0.45

Earnings vs. Estimates